Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1559325820979921 http://scihub22266oqcxt.onion/10.1177/1559325820979921 33402882!7745599!33402882     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Dose+Response 2020 ; 18 (4): 1559325820979921 Nephropedia Template TP {{tp|p=33402882|t=2020. Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China |pdf=|usr=}}{{33402882}} gab.com Text Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China JO: Dose Response http://www.kidney.de/pget.php?&tw=1&pmid=33402882 #FOAvip OBJECTIVE: To investigate clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) patients. METHODS: We included 4 severe patients and 3 critical patients. The date of admission to hospital ranged from January 30 to February 19, 2020. We retrospectively collected clinical and outcome data. Relative parameters were compared. RESULTS: After CP therapy, the symptoms and respiratory functions were improved. Median PaO(2)/FIO(2) increased from 254 (142-331) to 326 (163-364), and dependence of oxygen supply decreased. Median time to lesion's first absorption was 5 (2-7) days, undetectable viral RNA was 11 (3.5-15.7) days. Median lymphocyte count (0.77 x 10(9)/L vs 0.85 x 10(9)/L) and albumin level (31g/L vs 36 g/L) were elevated, C-reactive protein (44 mg/L vs 18 mg/L), D-dimer (5.9 mg/L vs 4 mg/L) and lactate dehydrogenase (263 U/L vs 245 U/L) decreased. No obvious adverse reactions were observed. At the follow-up on June 14, 2020, 6 patients had completely recovered and one died from terminal disease. CONCLUSION: CP therapy for COVID-19 was effective and safe. Three patients who did not combine with antiviral therapy after CP also obtained viral clearance and clinical improvement. However, CP therapy failed to save the life of a terminally ill patient. Twit Text FOAVip Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China ????Dose Response http://www.kidney.de/pget.php?&tw=1&pmid=33402882 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33402882 #FOAvip English Wikipedia <ref>{{Cite pmid|33402882}}</ref> Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China #MMPMID33402882 Hu X; Hu C; Jiang D; Zuo Q; Li Y; Wang Y; Chen X Dose Response 2020[Oct]; 18 (4): 1559325820979921 PMID33402882show ga OBJECTIVE: To investigate clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) patients. METHODS: We included 4 severe patients and 3 critical patients. The date of admission to hospital ranged from January 30 to February 19, 2020. We retrospectively collected clinical and outcome data. Relative parameters were compared. RESULTS: After CP therapy, the symptoms and respiratory functions were improved. Median PaO(2)/FIO(2) increased from 254 (142-331) to 326 (163-364), and dependence of oxygen supply decreased. Median time to lesion's first absorption was 5 (2-7) days, undetectable viral RNA was 11 (3.5-15.7) days. Median lymphocyte count (0.77 x 10(9)/L vs 0.85 x 10(9)/L) and albumin level (31g/L vs 36 g/L) were elevated, C-reactive protein (44 mg/L vs 18 mg/L), D-dimer (5.9 mg/L vs 4 mg/L) and lactate dehydrogenase (263 U/L vs 245 U/L) decreased. No obvious adverse reactions were observed. At the follow-up on June 14, 2020, 6 patients had completely recovered and one died from terminal disease. CONCLUSION: CP therapy for COVID-19 was effective and safe. Three patients who did not combine with antiviral therapy after CP also obtained viral clearance and clinical improvement. However, CP therapy failed to save the life of a terminally ill patient. äEffectiveness of Convalescent Plasma Therapy for COVID-19 Patients in (epmc).pdf DeepDyve Pubget Overpricing